Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Autoimmune Disorders

Free Subscription 29.09.2025 1 Am J Kidney Dis 1 Ann Neurol 1 Brain 2 Diabetes 1 J Autoimmun 5 J Clin Endocrinol Metab 1 J Neuroimmunol 3 J Neurol 1 J Pediatr Endocrinol Metab 2 Kidney Int 5 Lancet Neurol 4 Mult Scler 1 Neurol Clin Pract 4 Neurology 1 PLoS One 1 Thyroid

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Kidney Dis

1. BU L, Lee JH, Quigley MM, Elahimehr R, et al
   IgG3kappa Monoclonal Membranous Nephropathy Associated With Acquired Lecithin Cholesterol Acyltransferase Deficiency.
   Am J Kidney Dis. 2025 Sep 18:S0272-6386(25)01024.
   PubMed         Abstract available
   
   

   
   Ann Neurol

2. SIAVOSHI F, Smith MD, Cassard S, Moreau GB, et al
   Fasting Mimicking Diets Reverse Accelerated Biological Aging in Multiple Sclerosis.
   Ann Neurol. 2025 Sep 19. doi: 10.1002/ana.78044.
   PubMed         Abstract available
   
   

   
   Brain

3. FURLAN R, Schaedelin S, Frederiksen JL, Watanabe M, et al
   Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.
   Brain. 2025 Sep 24:awaf345. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Diabetes

4. ZHOU X, Iakovliev A, McGurnaghan S, Erabadda B, et al
   Genome-Wide Aggregated Trans Effects Analysis for Circulating Proteins Indicates a Key Role of Immune Checkpoints in Type 1 Diabetes.
   Diabetes. 2025 Aug 11:db250067. doi: 10.2337/db25-0067.
   PubMed         Abstract available
   
   
5. EVANS-MOLINA C, Dor Y, Lernmark A, Mathieu C, et al
   The Heterogeneity of Type 1 Diabetes: Implications for Pathogenesis, Prevention, and Treatment-2024 Diabetes, Diabetes Care, and Diabetologia Expert Forum.
   Diabetes. 2025 Jul 30:dbi250011. doi: 10.2337/dbi25-0011.
   PubMed         Abstract available
   
   

   
   J Autoimmun

6. LIU X, Wang C, Guan X
   Mitochondrial dysfunction is a potential key mechanism for atherosclerosis predisposition in patients with systemic lupus erythematosus.
   J Autoimmun. 2025;157:103488.
   PubMed         Abstract available
   
   

   
   J Clin Endocrinol Metab

7. GERA S, Rearson A, Baker G, Douvas JL, et al
   Changes in 90-Day Time in Range Among Youth with Type 1 Diabetes Initiating Different Automated Insulin Delivery Systems.
   J Clin Endocrinol Metab. 2025 Jan 15:dgaf006. doi: 10.1210.
   PubMed         Abstract available
   
   
8. JAHOOR F, Hsu JW, Keene KR, Peacock WF, et al
   Amino acids and CART distinguish A-beta+ Ketosis-Prone Diabetes from type 1 and type 2 diabetes during hyperglycemic crises.
   J Clin Endocrinol Metab. 2025 Jan 16:dgaf033. doi: 10.1210.
   PubMed         Abstract available
   
   
9. ABU IRSHEED G, Steffen A, Martyn-Nemeth P, Park M, et al
   Multidimensional Sleep Health, Glycemic Control, and Self-Reported Outcomes in Type 1 Diabetes: A Cross-Sectional Study.
   J Clin Endocrinol Metab. 2025 Jan 16:dgaf032. doi: 10.1210.
   PubMed         Abstract available
   
   
10. SHE R, Suvitaival T, Andersen HU, Hommel E, et al
    Metabolic Effects of Glucagon Stimulations in Type 1 Diabetes and Healthy Controls.
    J Clin Endocrinol Metab. 2025 Jan 20:dgaf030. doi: 10.1210.
    PubMed         Abstract available
    
    
11. CAMOIN M, Mohammedi K, Saulnier PJ, Hadjadj S, et al
    Body-weight Cycling and Risk of Diabetic Kidney Disease in People With Type 1 Diabetes in the DCCT/EDIC Population.
    J Clin Endocrinol Metab. 2025 Feb 4:dgae852. doi: 10.1210.
    PubMed         Abstract available
    
    

    
    J Neuroimmunol

12. MARTINEZ-MEDINA S, Olivas-Dominguez ER, Romero-Armenta RN, Avalos-Arias A, et al
    PERM associated with thymic carcinoma with triple-autoantibody positivity: case report and literature review.
    J Neuroimmunol. 2025;409:578753.
    PubMed         Abstract available
    
    

    
    J Neurol

13. ROMANO F, Rocca MA, Pagani E, Amato MP, et al
    Effects of cognitive rehabilitation and exercise on brain structure in progressive multiple sclerosis: results from the CogEx trial.
    J Neurol. 2025;272:645.
    PubMed         Abstract available
    
    
14. MORENO-NAVARRO L, Mora-Diaz S, Ruiz-Escribano-Menchen L, Sempere AP, et al
    Kappa free light chain index as a diagnostic and prognostic biomarker in multiple sclerosis.
    J Neurol. 2025;272:646.
    PubMed         Abstract available
    
    
15. HABEK M, Adamec I, Gabelic T, Barun B, et al
    Diagnostic performance of the 2010, 2017, and 2024 McDonald criteria: clinical implications in multiple sclerosis.
    J Neurol. 2025;272:637.
    PubMed         Abstract available
    
    

    
    J Pediatr Endocrinol Metab

16. NENEMAN J, Niedziela M, Dyrka K, Banaszak-Ziemska M, et al
    Endocrinopathies associated with pediatric common variable immunodeficiency.
    J Pediatr Endocrinol Metab. 2025;38:946-955.
    PubMed         Abstract available
    
    

    
    Kidney Int

17. FLOEGE J, Barratt J, Cook HT, Noronha IL, et al
    Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).
    Kidney Int. 2025;108:548-554.
    PubMed         Abstract available
    
    
18. THEIS JD, Nasr SH, Sethi S
    Absence of PCDH7-associated dual antigens in membranous nephropathy.
    Kidney Int. 2025;108:707-708.
    PubMed        
    
    

    
    Lancet Neurol

19. GALETTA SL, Bennett JL
    Shedding new light on the diagnosis of multiple sclerosis.
    Lancet Neurol. 2025;24:807-808.
    PubMed        
    
    
20. FOX RJ, Jones SE
    Translating MRI advances into multiple sclerosis diagnosis: bridging science and clinical practice.
    Lancet Neurol. 2025;24:808-810.
    PubMed        
    
    
21. MONTALBAN X, Lebrun-Frenay C, Oh J, Arrambide G, et al
    Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria.
    Lancet Neurol. 2025;24:850-865.
    PubMed         Abstract available
    
    
22. BARKHOF F, Reich DS, Oh J, Rocca MA, et al
    2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis.
    Lancet Neurol. 2025;24:866-879.
    PubMed         Abstract available
    
    
23. SAIDHA S, Green AJ, Leocani L, Vidal-Jordana A, et al
    The use of optical coherence tomography and visual evoked potentials in the 2024 McDonald diagnostic criteria for multiple sclerosis.
    Lancet Neurol. 2025;24:880-892.
    PubMed         Abstract available
    
    

    
    Mult Scler

24. UYSAL TAN F, Tan MO
    Comment on 'short- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis'.
    Mult Scler. 2025 Sep 22:13524585251380003. doi: 10.1177/13524585251380003.
    PubMed        
    
    
25. CAROLUS B, Dequirez PL, Olivier L, Hafez S, et al
    Response to the letter by Uysal Tan and Tan regarding our article "short- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis".
    Mult Scler. 2025 Sep 22:13524585251380411. doi: 10.1177/13524585251380411.
    PubMed        
    
    
26. SHIPLEY J, Beadnall HN, Sanfilippo PG, Horakova D, et al
    Disease course after pregnancy in women with progressive multiple sclerosis symptoms.
    Mult Scler. 2025 Sep 20:13524585251368248. doi: 10.1177/13524585251368248.
    PubMed         Abstract available
    
    
27. SALAZAR-CAMELO A, Vega L, Fadlallah Y, Bou Rjeily N, et al
    Finite-course ocrelizumab in relapsing multiple sclerosis: Results of two prospective open-label trials with matched controls.
    Mult Scler. 2025 Sep 19:13524585251375350. doi: 10.1177/13524585251375350.
    PubMed         Abstract available
    
    

    
    Neurol Clin Pract

28. LI P, Lin JK, Klebanoff MJ, Palkar R, et al
    Reducing the Out-of-Pocket Costs of Disease-Modifying Therapies for Medicare Beneficiaries With Multiple Sclerosis.
    Neurol Clin Pract. 2025;15:e200536.
    PubMed         Abstract available
    
    

    
    Neurology

29. PORTACCIO E, Betti M, De Meo E, Pasto L, et al
    Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple Sclerosis.
    Neurology. 2025;105:e213977.
    PubMed         Abstract available
    
    
30. O'NEILL KA, Charvet L, Waltz M, George A, et al
    Cognitive Function in People With Pediatric Multiple Sclerosis Over 2 Years.
    Neurology. 2025;105:e214142.
    PubMed         Abstract available
    
    
31. OLIVIERI E, Muller J, Toosy AT
    Predicting Disability Using PIRA in Multiple Sclerosis: Is It as Straightforward as It Appears?
    Neurology. 2025;105:e214206.
    PubMed        
    
    
32. PORTACCIO E, Amato MP
    Moving Closer to the Prevention of Cognitive Disability in People With Pediatric-Onset Multiple Sclerosis.
    Neurology. 2025;105:e214244.
    PubMed        
    
    

    
    PLoS One

33. LI L, Olcer M, Wang Z, Song Y, et al
    IFN-beta therapy rescues dysregulated IFN-stimulated proteins, serum cytokines, and neurotrophic factors in multiple sclerosis: Multiplex analysis of short-term and long-term IFN responses.
    PLoS One. 2025;20:e0330867.
    PubMed         Abstract available
    
    

    
    Thyroid

34. POLKAMPALLY S, Halagur AS, Green A, Wei E, et al
    Incidence of Pediatric Graves' Disease in the United States: An Epidemiological Analysis of 2007-2022 Outpatient Insurance Claims.
    Thyroid. 2025 Sep 22. doi: 10.1177/10507256251382559.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.